LBPS 4D pharma plc ADRs

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.? 4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

$12.59  -0.14 (-1.10%)
As of 04/13/2021 16:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  03/22/2021
Outstanding shares:  22,373,048
Average volume:  27,073
Market cap:   $281,676,674
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Valuation   (See tab for details)
PE ratio:   -39.51
PB ratio:   9.69
PS ratio:   512.14
Return on equity:   -24.54%
Net income %:   -4,991.27%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy